BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...acquired Endocyte Inc. for $2.1 billion, obtaining 177Lu-PSMA-617...
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

...solid tumors. It presented on bispecifics targeting PSMA...
...Programmed cell death 1 ligand 1PSMA (FOLH1; GCPII...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...tumors expressing IGF-1R. Novartis has a peptide-conjugated, PSMA-targeting...
...Insulin-like growth factor-1 receptor PSMA (FOLH1; GCPII) – Prostate-specific membrane antigen Karen...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...on its half-life extended Bispecific T cell Engager (BiTE) platform, showing that AMG 160, a PSMA...
...neu) – Epidermal growth factor receptor 2PD-1 (PDCD1; CD279) – Programmed cell death 1PSMA (FOLH1; GCPII...
BioCentury | Aug 22, 2020
Emerging Company Profile

Luminary: turning cell engineering tools into therapies

...I study of CAR T cell therapy P-PSMA-101...
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

...after disclosing a clinical hold on its Phase I study of CAR T cell therapy P-PSMA-101...
...is marketed in Japan for chronic constipation, did meet the Phase II trial’s primary endpoint. TARGETSPSMA (FOLH1; GCPII...
...membrane antigenSLC10A2 (ASBT; IBAT) - Solute carrier family 10 sodium-dependent bile acid transporter member 2 BC Staff P-PSMA-101 Goofice...
BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

...in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and PSMA...
...growth factor receptor JAK-2 - Janus kinase-2 PARP - poly(ADP-ribose) polymerase PSMA (FOLH1) (GCPII) - Prostate-specific membrane antigen...
...member BioCentury Staff Regeneron Pharmaceuticals Inc. Genentech Inc. Roche Dana-Farber Cancer Institute Allen Institute National Institute on Aging Broad Institute of MIT and Harvard CD28 Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Programmed...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...present interim Phase I data from HPN424, a Tri-specific T cell Activating Construct (TriTAC) targeting PSMA...
...1 PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 PSMA (FOLH1; GCPII) - Prostate-specific membrane antigen...
BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

...formation is required for full T cell activation. In cell-based assays, STOP-CAR T cells targeting PSMA...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...III testing for PSMA-positive metastatic CRPC due to read out in 2020. Endocyte had bought 177Lu-PSMA-617...
...types.” The company’s pipeline of Targeted Thorium Conjugates (TTC) includes three Phase I agents targeting PSMA...
...Targets HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 PSMA (FOLH1; GCPII) - Prostate-specific membrane antigen...
Items per page:
1 - 10 of 326